BC017647 Inhibitors
Chemical inhibitors of BC017647 act through various mechanisms to regulate its activity by targeting different components of signaling pathways. Wortmannin and LY294002 are two such inhibitors that directly target phosphoinositide 3-kinases (PI3K), a group of enzymes that are crucial for the activation of BC017647. By inhibiting PI3K, these chemicals prevent the phosphorylation and subsequent activation of downstream targets including BC017647. Rapamycin, on the other hand, specifically impedes the mechanistic target of rapamycin (mTOR), another kinase critical in the same pathway as PI3K. The inhibition of mTOR by rapamycin leads to a decrease in BC017647 activity due to its dependence on mTOR signaling for activation. Similarly, U0126 and SB203580 target upstream kinases MEK1/2 and p38 MAP kinase, respectively. Inhibition of these kinases by U0126 and SB203580 results in reduced phosphorylation of downstream targets, which includes BC017647, thereby dampening its activity.
Further regulating BC017647, Staurosporine serves as a broad-spectrum kinase inhibitor that can affect a myriad of kinases responsible for the phosphorylation of BC017647. In contrast, PP2 is more selective, targeting Src family tyrosine kinases which, when inhibited, reduce the activation state of BC017647. PD168393 works by irreversibly inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, a receptor that can activate several downstream pathways involving BC017647. SP600125 and NF449 exhibit their regulatory effects by inhibiting c-Jun N-terminal kinase (JNK) and the Gs-alpha subunit of G-proteins, respectively. The inhibition of JNK by SP600125 and the G-protein signaling by NF449 both lead to a decrease in BC017647 activity. Lastly, Bisindolylmaleimide I and Genistein target Protein Kinase C (PKC) and tyrosine kinase activities, respectively. The inhibition of PKC by Bisindolylmaleimide I and the blockade of tyrosine kinase activity by Genistein result in lower activation levels of BC017647.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K), which are upstream regulators in many signaling pathways. By inhibiting PI3K, downstream signaling to proteins such as BC017647 that depend on PI3K for activation or stabilization is inhibited. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mechanistic target of rapamycin (mTOR), a key kinase in the PI3K/AKT/mTOR pathway. Given that BC017647 is part of this pathway, inhibition of mTOR leads to reduced activity of BC017647. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a selective inhibitor of PI3Ks. Inhibition of PI3K prevents the phosphorylation and activation of downstream targets, including BC017647, thereby inhibiting its function. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It can inhibit a broad range of kinases that would phosphorylate BC017647, leading to a decrease in its functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2. MEK1/2 are kinases that act upstream of ERK, which can regulate proteins like BC017647. Inhibition of MEK1/2 by U0126 therefore results in decreased phosphorylation and inhibition of BC017647. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. By inhibiting p38 MAP kinase, the phosphorylation of downstream proteins such as BC017647 is decreased, leading to inhibition of its activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Src kinases can phosphorylate and activate a variety of downstream proteins, and inhibiting them with PP2 would result in reduced activation of BC017647. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
PD168393 irreversibly inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. Since EGFR can activate several downstream pathways that may include BC017647, inhibition by PD168393 results in reduced activity of BC017647. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is involved in stress and inflammatory responses and can modulate the activity of many proteins. Inhibition of JNK by SP600125 will lead to decreased activity of BC017647. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449 is a potent and selective inhibitor of the Gs-alpha subunit of G-proteins. Inhibition of this subunit prevents activation of the entire G-protein and its downstream effects, including activation of proteins like BC017647. | ||||||